Joel Greenblatt’s Altimmune ALT Stock Holding History

Joel Greenblatt’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,669	Closed	-$45.7K	–	1759
2025 Q4	$45.7K	Buy	+12,669	New	+$55.2K	﹤0.01%	1709

Other funds holding ALT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Joel Greenblatt's ALT Position: Q1 2026 in Review

Joel Greenblatt sold out of Altimmune (ALT) in Q1 2026, closing a stake of 12,669 shares — an estimated $45.7K sold.

Joel Greenblatt first reported a position in ALT in Q4 2025 and held it in 1 quarter. The position peaked at $45.7K in Q4 2025. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.

Joel Greenblatt reported no remaining Altimmune position as of Q1 2026 after selling out during the quarter.
Joel Greenblatt sold 12,669 Altimmune shares in Q1 2026, an estimated $45.7K.
Joel Greenblatt first reported a position in Altimmune in Q4 2025 and held it in 1 quarter.
Joel Greenblatt's Altimmune position peaked at $45.7K in Q4 2025.
173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.

Based on Gotham Asset Management's 13F filing for Q1 2026, filed 15 May 2026.